Review shows combined strategies improve treatment outcomes for epithelial ovarian cancer, indicating potential of new therapies.
Key Points
Combined strategies enhance treatment efficacy for epithelial ovarian cancer, addressing challenges faced with monotherapy.
Emerging therapies like Bevacizumab, Olaparib, and Pembrolizumab are being integrated into treatment protocols to improve patient outcomes.
Analysis of current trials reveals innovations in targeted therapy that aim to reduce adverse reactions linked to traditional methods.
Highlighting significant advancements in combinations of biological drugs, this review stresses their potential to benefit patients with advanced-stage ovarian cancer.